July 12th 2024
An analysis of interaction checkers and product summaries revealed large differences in the consistency and reliability of providing accurate information on potential drug-drug interactions.
FDA Approves Upadacitinib for Adults With Moderately to Severely Active Crohn Disease
May 18th 2023In clinical trials of patients with Crohn disease, upadacitinib demonstrated early and long-term symptom relief, as well a visible reduction of damage to the intestinal lining caused by excess inflammation.
Read More